



Chaoju Eye Care Holdings Limited 朝聚眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

Stock code : 2219

INTERIM REPORT 2022



CONTENTS

Corporate Information	2
Financial Highlights	4
Corporate Profile	5
Management Discussion and Analysis	6
Other Information	28
Independent Review Report	34
Interim Condensed Consolidated Statement of Profit or Loss	35
Interim Condensed Consolidated Statement of Comprehensive Income	36
Interim Condensed Consolidated Statement of Financial Position	37
Interim Condensed Consolidated Statement of Changes in Equity	39
Interim Condensed Consolidated Statement of Cash Flows	41
Notes to the Interim Condensed Consolidated Financial Information	43
Definitions & Glossary	57



Corporate Information

BOARD OF DIRECTORS

Executive Directors

Mr. Zhang Bozhou (*Chairman and Chief Executive Officer*)

Ms. Zhang Xiaoli

Mr. Zhang Junfeng

Mr. Zhang Guangdi

Non-executive Directors

Mr. Ke Xian

Mr. Richard Chen Mao

Mr. Li Zhen

Ms. Zhang Wenwen

Independent non-executive Directors

Mr. He Mingguang

Ms. Guo Hongyan

Mr. Li Jianbin

Mr. Bao Shan

AUDIT COMMITTEE

Mr. Li Jianbin (*Chairman*)

Ms. Guo Hongyan

Mr. Bao Shan

REMUNERATION COMMITTEE

Mr. Bao Shan (*Chairman*)

Mr. Li Jianbin

Mr. Zhang Bozhou

NOMINATION COMMITTEE

Mr. Zhang Bozhou (*Chairman*)

Mr. Bao Shan

Mr. He Mingguang

COMPANY SECRETARIES

Ms. Xie Chun (*Appointed on June 22, 2022*)

Mr. Cheng Ching Kit

AUTHORISED REPRESENTATIVES

Mr. Zhang Bozhou

Mr. Cheng Ching Kit

REGISTERED OFFICE

Harneys Fiduciary (Cayman) Limited

4th Floor, Harbour Place

103 South Church Street

P.O. Box 10240

Grand Cayman KY1-1002

Cayman Islands

HEADQUARTER AND PRINCIPAL PLACE OF BUSINESS IN THE PRC

24/F, East Zone
Block A, Shouke Building
No. 14 Yard, West 3rd Ring South Road
Fengtai District
Beijing
China

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

40th Floor
Dah Sing Financial Centre
No. 248 Queen's Road East
Wanchai
Hong Kong

CAYMAN ISLANDS PRINCIPAL SHARE REGISTRAR AND TRANSFER AGENT

Harneys Fiduciary (Cayman) Limited
4th Floor, Harbour Place
103 South Church Street
P.O. Box 10240
Grand Cayman KY1-1002
Cayman Islands

HONG KONG SHARE REGISTRAR

Computershare Hong Kong Investor Services Limited
Shops 1712-1716
17/F, Hopewell Centre
183 Queen's Road East
Wanchai
Hong Kong

HONG KONG LEGAL ADVISOR

Fangda Partners
26/F, One Exchange Square
8 Connaught Place
Central
Hong Kong

AUDITOR

Ernst & Young
Certified Public Accountants
Registered Public Interest Entity Auditor
27/F, One Taikoo Place
979 King's Road
Quarry Bay
Hong Kong

COMPLIANCE ADVISOR

Haitong International Capital Limited
Suites 3001-3006 and 3015-3016
One International Finance Centre
1 Harbour View Street
Central
Hong Kong

STOCK CODE

2219

COMPANY WEBSITE

www.chaojueye.com

Financial Highlights

	Six months ended June 30,		Change
	2022	2021	
	RMB'000	RMB'000	
	(Unaudited)	(Unaudited)	
Operating Results			
Revenue	532,742	500,171	6.5%
Gross profit	244,336	227,350	7.4%
Profit before tax	131,211	106,011	23.8%
Net profit	101,761	78,671	29.4%
Non-IFRS adjusted net profit ⁽¹⁾	103,250	98,606	4.8%
Profitability			
Gross profit margin	45.9%	45.5%	
Net profit margin	19.1%	15.7%	
Non-IFRS adjusted net profit margin ⁽²⁾	19.4%	19.7%	

	As at	As at	Change
	June 30,	December 31,	
	2022	2021	
	RMB'000	RMB'000	
	(Unaudited)	(Audited)	
Financial Position			
Total assets	2,598,662	2,506,514	3.7%
Total equity	2,197,414	2,128,406	3.2%
Total liabilities	401,248	378,108	6.1%
Cash and cash equivalents	1,414,424	1,257,136	12.5%

Notes:

- (1) Non-IFRS adjusted net profit was calculated as net profit for the Reporting Period excluding share-based compensation expenses.
- (2) Non-IFRS adjusted net profit margin was calculated based on non-IFRS adjusted net profit divided by revenue.

Corporate Profile

The Group is a leading ophthalmic medical service group in North China with a strong reputation nationwide. The Group was founded in 1988 in Baotou, Inner Mongolia, as a clinic providing ophthalmic services. Since its inception, the Group adheres to the vision of “Being a Leader of Happy Ophthalmic Healthcare” (成為全球快樂眼健康引領者) and has been providing its patients with a safe, reassuring and pleasant ophthalmic medical experience with the aid of effective medical equipment and technology as well as professional, caring and considerate services.

The Group generates revenue primarily from (i) consumer ophthalmic services, and (ii) basic ophthalmic services. Consumer ophthalmic services include treatments and prevention of various types of ophthalmic disorders, including refractive correction (including presbyopia correction), myopia control and provision of optical products and services, the costs for which are currently not covered by public health insurance programs. Basic ophthalmic services include treatments of a wide range of common eye diseases, including cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases and pediatric eye diseases, the cost of which are generally eligible to be covered by public health insurance programs. In light of upgraded social consumption in China over the recent years, the Group plans to increase its strategic focus on its consumer ophthalmic services business and devote more efforts to continue its rapid growth, while maintaining its fundamental strength in basic ophthalmic business.

The Group’s patients are treated by ophthalmologists equipped with advanced technology and equipment. The Group has a deep bench of ophthalmic experts with medical expertise and rich experience. Advanced technology and equipment is another key factor underpinning its market leadership. Baotou Hospital is the one-and-only ophthalmic hospital in Inner Mongolia with a preparation room to produce hospital-made traditional Chinese medicine capsules and eye drops. It is also one of the few medical service providers in China that are qualified to produce 0.01% atropine sulfate eye drops to be prescribed within the respective hospitals to control myopia among adolescents. The Group believes that its capabilities in hospital-made pharmaceuticals have helped improve its brand awareness and customer loyalty, which has brought the Group with competitive advantage in the area of myopia control and increased its overall revenue.

The Group believes that the following competitive strengths have differentiated itself from its competitors:

- As a leading ophthalmic medical service group in North China, the Group is well-positioned to capture significant demands from a vast market for ophthalmic services.
- The Group’s clustered operation model helps to improve our market penetration, operational efficiency and profitability.
- The Group’s centralized and standardized management system makes its business model scalable and replicable.
- The Group has a team of high-caliber medical professionals and a sound training system underpinning the foundation of its growth.
- The Group’s full-service clinical ophthalmic treatments bring high customer satisfaction.
- The Group has garnered significant support from its experienced management team as well as its Shareholders.

Management Discussion and Analysis

BUSINESS UPDATES

As of June 30, 2022, the Group operated a network of 18 ophthalmic hospitals and 25 optical centers spanning across five provinces or autonomous region in China. The ophthalmic hospitals specialize in providing ophthalmic services and the optical centers offer a series of optical products and services to satisfy a wide array of requests from customers.

In January 2022, Hohhot No. 2 Hospital has obtained the necessary licenses and subsequently commenced business in February 2022. In May 2022, Hangzhou Chaoju Ophthalmic Optometry Eyeglasses Co., Ltd.* (杭州朝聚眼視光眼鏡有限公司) has completed the industrial and commercial registration and subsequently commenced business.

The following table sets forth a breakdown of certain operational information by type of services provided for the periods indicated:

	Unaudited Six months ended June 30,	
	2022	2021
The hospitals		
Out-patient services		
Number of out-patient visits	439,780	412,974
Average spending per visit (RMB)	728	711
In-patient services		
Number of in-patient visits	22,510	21,998
Average spending per visit (RMB)	7,750	7,593
Optical centers		
Number of customer visits ⁽¹⁾	55,339	57,049
Average selling price (RMB) ⁽²⁾	692	684

Notes:

- (1) Represents the total number of purchases made by customers at the optical centers. If a customer makes more than one purchase at the optical centers within the same day, he/she will only be counted once. If a customer purchases at the optical centers on different days, he/she will be counted according to the number of days he/she made purchases at the optical centers.
- (2) Represents the average selling price calculated by the total revenue generated from the optical centers by the total number of customer visits.

The Group's revenue increased by 6.5% from RMB500.2 million for the six months ended June 30, 2021 to RMB532.7 million for the six months ended June 30, 2022, primarily attributable to the increase in revenue from consumer ophthalmic services, and to a lesser extent, revenue generated from basic ophthalmic services.

The following table sets forth a breakdown of revenue by business segments for the periods indicated:

	Unaudited			
	Six months ended June 30,			
	2022		2021	
	Revenue	Percentage	Revenue	Percentage
	(RMB'000)	of revenue	(RMB'000)	of revenue
Consumer ophthalmic services	291,051	54.6%	266,495	53.3%
Basic ophthalmic services	241,691	45.4%	233,002	46.6%
Others	–	–	674	0.1%
Total	532,742	100.0%	500,171	100.0%

Consumer ophthalmic services

The Group's consumer ophthalmic services include treatments and prevention of various types of ophthalmic disorders, including refractive correction (including presbyopia correction), myopia control and provision of optical products and services, the costs for which are currently not covered by public health insurance programs.

To maintain the Group's strong reputation in the provision of consumer ophthalmic services and in response to the impact of the COVID-19 pandemic in the first half of 2022, the Group (i) optimized its marketing and promotion activities with a focus on online promotion, new media and other online channels; (ii) formulated operational management measures to optimize its customer membership management model for maintaining customer loyalty; and (iii) streamlined the admission process and increased the Group's reception capacity for patient visits in preparation for the lifting of pandemic control measures. The Group continued to reinforce the training on consumer ophthalmic services techniques and related skills and improve the service quality in adherence to the Group's core values of "Providing its patients with a safe, reassuring and pleasant ophthalmic medical experience". Furthermore, the Group also implemented stringent medical quality control measures in providing quality medical services to its patients, enhancing the Group's reputation.

In addition, consumer ophthalmic services are usually more profitable as it is not subject to the pricing guidance imposed by public health insurance authorities and as such the Group devoted more resources to pursue continuous and rapid growth of consumer ophthalmic services. For the six months ended June 30, 2022, the Group's consumer ophthalmic services contributed to 54.6% of the Group's total revenue, representing an increase of approximately 1.3% compared to the same period in 2021.

Management Discussion and Analysis

Basic ophthalmic services

The Group's basic ophthalmic services include treatments of a wide range of common eye diseases, including cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases and pediatric eye diseases, the cost of which are generally eligible to be covered by public health insurance programs.

For the six months ended June 30, 2022, the Group devoted more on its marketing initiatives and optimized its marketing solutions, which resulted in an increase in the number of patient visits. The Group procured advance medical equipment for the treatment of eye diseases and expanded the use of advanced treatment regime and high-end medical devices and consumables, which increased the average spending per patient visit. The Group also maintained its medical professionalism and quality medical services, which improved the retention rate of patients returning to the Group's ophthalmic hospitals to receive treatment on their other eye for basic eye diseases, such as cataracts, which further increased the revenue generated from basic ophthalmic services.

Although the revenue of consumer ophthalmic services continued to increase, the revenue of basic ophthalmic services continued to grow steadily, and continues to be a key component that allows the Group to maintain its market share and influence. For the six months ended June 30, 2022, the Group's basic ophthalmic services contributed to 45.4% of the Group's total revenue.

Gross Profit and Gross Profit Margin

The following table sets forth a breakdown of gross profit by business segments and the corresponding gross profit margin for the periods indicated:

	Unaudited			
	Six months ended June 30,		2021	
	2022			
	Gross profit (RMB'000)	Gross profit margin	Gross profit (RMB'000)	Gross profit margin
Consumer ophthalmic services	146,792	50.4%	138,535	52.0%
Basic ophthalmic services	97,544	40.4%	88,740	38.1%
Others	–	–	75	11.1%
Total	244,336	45.9%	227,350	45.5%

The gross profit generated from consumer ophthalmic services was RMB146.8 million for the six months ended June 30, 2022, representing an increase of 6.0% compared to the six months ended June 30, 2021. This was primarily due to an increase in revenue from consumer ophthalmic services of 9.2% compared to the same period last year, and the expansion of the consumer ophthalmic services business resulted in the dilution of related costs. The gross profit generated from basic ophthalmic services was RMB97.5 million for the six months ended June 30, 2022, representing an increase of 9.9% compared to the six months ended June 30, 2021. This was primarily due to an increase in revenue from basic ophthalmic services of 3.7% compared to same period last year and the dilution of related costs. The increase in the Group's total gross profit was primarily attributable to (i) an increase in total revenue of 6.5% compared to the same period last year; and (ii) the increase in revenue contribution from consumer ophthalmic services to the Group's revenue by 1.3% compared to the same period last year, which has a higher gross profit margin compared to basic ophthalmic services.

The Group's Hospital Network

As of June 30, 2022, the Group operated a network of 18 ophthalmic hospitals spanning across five provinces or autonomous region in China, all of which were specialized in providing ophthalmic services. In addition, the Group also provides outpatient services through two clinics, namely the Tumb Right Banner branch of the Baotou Hospital and the Pingzhuang clinic of the Chifeng Hospital, which are branches of Baotou Hospital and Chifeng Hospital, respectively. The Group's hospitals offer a wide range of ophthalmic services, including out-patient and in-patient treatments and surgeries. The Group's clinics only offer out-patient diagnosis and treatments for relatively simple ophthalmic diseases and disorders and do not perform any surgeries.

The Group's hospitals are strategically located in five major regions, namely western Inner Mongolia and its adjacent region, eastern Inner Mongolia and its adjacent region, eastern Zhejiang, northern Zhejiang and northern Jiangsu. The Group has established a leading position in western Inner Mongolia and its adjacent region through its dense network layout of seven hospitals as of June 30, 2022. Leveraging the Group's market presence and experience in such region as well as its highly standardized management and services models, the Group has successfully established and acquired 11 hospitals in other regions as of June 30, 2022, consisting of five hospitals in eastern Inner Mongolia and its adjacent region, three hospitals in eastern Zhejiang, one hospital in northern Zhejiang and two hospitals in northern Jiangsu. Set out below is an illustration of the locations of the Group's hospitals as of June 30, 2022.



- Western Inner Mongolia and the adjacent region
- Eastern Inner Mongolia and the adjacent region
- Eastern Zhejiang
- Northern Zhejiang
- Northern Jiangsu

The following table sets forth certain key information of the Group's hospitals as of June 30, 2022.

	Hospital	Location	Class⁽¹⁾	Date of Incorporation	GFA (sq.m.)	Facilities Number of registered beds⁽²⁾
1	Baotou Hospital	Western Inner Mongolia	Class III	May 12, 2016	15,710	120
2	Hohhot Hospital	Western Inner Mongolia	Class III	September 21, 2016	7,697	100
3	Datong Hospital	Adjacent to western Inner Mongolia	Class III	March 24, 2015	4,319	50
4	Ulanqab Hospital	Western Inner Mongolia	N/A	March 27, 2017	3,100	60
5	Baotou Kunlun Hospital	Western Inner Mongolia	Class II	March 7, 2016	2,968	30
6	Dalad Banner Hospital	Western Inner Mongolia	Class II	May 23, 2016	2,292	30
7	Hohhot No. 2 Hospital	Western Inner Mongolia	Class II	November 3, 2016	3,980	30
8	Hulunbuir Hospital	Eastern Inner Mongolia	Class II	February 14, 2018	3,772	30
9	Chifeng Hospital	Eastern Inner Mongolia	Class III	December 19, 2016	7,662	100
10	Tongliao Hospital	Eastern Inner Mongolia	Class II	September 20, 2017	4,568	60
11	Chengde Hospital	Adjacent to eastern Inner Mongolia	Class II	December 2, 2016	7,579	80
12	Xiilinhote Hospital	Eastern Inner Mongolia	Class II	December 16, 2014	1,070	30
13	Ningbo Hospital	Eastern Zhejiang	Class II	Acquired ⁽³⁾	4,510	30
14	Ninghai Hospital	Eastern Zhejiang	Class II	Acquired ⁽⁴⁾	2,798	20
15	Xiangshan Hospital	Eastern Zhejiang	N/A	Acquired ⁽⁵⁾	2,763	35
16	Jiaxing Hospital	Northern Zhejiang	Class II	February 7, 2018	6,937	60
17	Siyang Hospital	Northern Jiangsu	N/A	July 21, 2016	4,200	30
18	Sihong Hospital	Northern Jiangsu	N/A	June 28, 2017	5,201	60
	Total				91,126	955

Notes:

- (1) Represents the classification of hospitals assigned by NHC or its local counterparts, with Class III being the highest classification and Class I being the lowest classification. "N/A" indicates that the relevant hospital was not assigned any classification by NHC or any of its local counterparts as of June 30, 2022, as the application for such classification of hospitals is not mandatory under the applicable laws and regulations.
- (2) Represents the number of beds registered in the practicing license of the respective hospital as of June 30, 2022.
- (3) The Group acquired Ningbo Hospital in December 2017.
- (4) The Group acquired Ninghai Hospital in June 2018.
- (5) The Group acquired Xiangshan Hospital in December 2017.

Management Discussion and Analysis

The Group's Optical Center Network

The Group locates its optical centers in areas with highly desirable retail developments and surrounded by dense concentration of target customers, and usually at locations inside or adjacent to its hospitals to facilitate optometry screening services for customers. The Group maintains a disciplined approach to open new optical centers and conduct market research before selecting a new site based on customer demographics and information from its existing customer database. As of June 30, 2022, the Group operated a network of 25 optical centers under the brand Chaoju (朝聚), strategically located in five major regions, namely the western Inner Mongolia and its adjacent region, eastern Inner Mongolia and its adjacent region, eastern Zhejiang, northern Zhejiang and northern Jiangsu, among which, there were 11 optical centers in western Inner Mongolia and its adjacent region, eight optical centers in eastern Inner Mongolia and its adjacent region, one optical center in eastern Zhejiang, three optical centers in northern Zhejiang and two optical centers in northern Jiangsu.

The table below sets forth a list of the Group's optical centers as of June 30, 2022 and its locations.

Optical center	Location
1 Baotou City Chaoju Optometry Correction Eyeglasses Co., Ltd.* (包頭市朝聚眼視光矯治配鏡有限公司)	Western Inner Mongolia
2 Baotou City Kunlun Chaoju Optometry Correction Eyeglasses Co., Ltd.* (包頭市昆侖朝聚眼視光矯治配鏡有限責任公司)	Western Inner Mongolia
3 Hohhot City Chaoju Optometry Correction Eyeglasses Co., Ltd.* (呼和浩特市朝聚眼視光矯治配鏡有限公司)	Western Inner Mongolia
4 Ulanqab City Chaoju Optometry Correction Eyeglasses Co., Ltd.* (烏蘭察布市朝聚眼視光矯治配鏡有限公司)	Western Inner Mongolia
5 Datong City Chaoju Eyeglasses Co., Ltd.* (大同市朝聚眼鏡有限公司)	Adjacent to western Inner Mongolia
6 Dalad Banner Chaoju Optometry Eyeglasses Co., Ltd.* (達拉特旗朝聚驗光配鏡有限公司)	Western Inner Mongolia
7 Jungar Banner Chaoju Optometry Eyeglasses Co., Ltd.* (准格爾旗朝聚驗光配鏡有限公司)	Western Inner Mongolia
8 Baotou City Donghe District Chaoju Optometry Eyeglasses Co., Ltd.* (包頭市東河區朝聚驗光配鏡有限公司)	Western Inner Mongolia
9 Tumb Right Banner Chaoju Optometry Eyeglasses Co., Ltd.* (土默特右旗朝聚驗光配鏡有限公司)	Western Inner Mongolia
10 Baotou Low Vision Rehabilitation Center (包頭市低視力康復中心)	Western Inner Mongolia
11 Hohhot Chaoju Optical Glasses Co., Ltd.* (呼和浩特市朝聚光學眼鏡有限公司)	Western Inner Mongolia

Optical center	Location
12 Chengde Chaoju Trading Co., Ltd.* (承德朝聚商貿有限公司)	Adjacent to eastern Inner Mongolia
13 Hexigten Banner Chaoju Ophthalmic Optometry Clinic Co., Ltd.* (克什克騰旗朝聚眼科視光門診有限公司)	Eastern Inner Mongolia
14 Xilinhot City Chaoju Optometry Correction Eyeglasses Co., Ltd.* (錫林浩特市朝聚眼視光矯治配鏡有限公司)	Eastern Inner Mongolia
15 Hulunbuir City Chaoju Optometry Co., Ltd.* (呼倫貝爾市朝聚眼視光有限公司)	Eastern Inner Mongolia
16 Tongliao City Chaoju Eyeglasses Co., Ltd.* (通遼市朝聚眼鏡有限責任公司)	Eastern Inner Mongolia
17 Ongniud Banner Chaoju Optometry Eyeglasses Co., Ltd.* (翁牛特旗朝聚驗光配鏡有限責任公司)	Eastern Inner Mongolia
18 Chifeng City Yuanbaoshan District Chaoju Optometry Eyeglasses Co., Ltd.* (赤峰市元寶山區朝聚驗光配鏡有限責任公司)	Eastern Inner Mongolia
19 Chifeng Chaoju Eyeglasses Co., Ltd.* (赤峰朝聚眼鏡有限責任公司)	Eastern Inner Mongolia
20 Zhoushan Chaoju Optical Glasses Co., Ltd.* (舟山朝聚光學眼鏡有限公司)	Eastern Zhejiang
21 Hangzhou Chaoju Optical Eyeglasses Co., Ltd.* (杭州朝聚光學眼鏡有限公司)	Northern Zhejiang
22 Jiaxing City Chaoju Optical Glasses Co., Ltd.* (嘉興市朝聚光學眼鏡有限公司)	Northern Zhejiang
23 Hangzhou Chaoju Ophthalmic Optometry Eyeglasses Co., Ltd.* (杭州朝聚眼視光眼鏡有限公司)	Northern Zhejiang
24 Siyang Chaoju Eyeglasses Co., Ltd.* (泗陽朝聚眼鏡有限公司)	Northern Jiangsu
25 Sihong County Chaoju Optical Optometry Eyeglasses Co., Ltd.* (泗洪縣朝聚視光配鏡有限公司)	Northern Jiangsu

Management Discussion and Analysis

Team of Medical Professionals

The Group has a deep bench of ophthalmic experts with medical expertise and rich experience to treat a wide range of eye diseases and to provide various types of consumer ophthalmic services. The Group focuses on the quality of ophthalmic services and devotes resources to allow its ophthalmologists to provide ophthalmic medical services in a professional, dedicated and responsible manner. The Group is also committed to recruiting and cultivating qualified professionals to form an ophthalmic medical team with outstanding professional and ethical standards and strong sense of responsibility. As of June 30, 2022, the Group had a total of 1,015 full-time medical professionals, among which, is composed of 207 physicians, 449 nurses and 359 other medical professionals. Among the 207 physicians, 178 of the full-time physicians were registered as specialized ophthalmologists. In addition, the Group also had 77 multi-site practice physicians who were full-time employees of other medical institutions.

In collaboration with Baotou Medical College of Inner Mongolia University of Science and Technology (內蒙古科技大學包頭醫學院), the Company applied to the Ministry of Education of the PRC with respect to the establishment of a new undergraduate specialization in optometry and its application was approved in the first half of 2022. The optometry specialization plans to enrol 40 students and vacancies for the 2022 Autumn semester intake have already been filled in August 2022. The successful establishment of this specialization shall serve as a crucial source of ophthalmologists for the Group in the future.

Awards, Recognitions and Social Responsibility

The Group provides charitable medical aid and free medical consultations to public institutions and disadvantaged communities from time to time. Such charitable events allow the Company to maintain good relationships with government authorities and agencies while simultaneously promote its ophthalmic and optical services. These events do not only benefit the disadvantaged communities, but also improve our brand awareness and reputation. For example, in the first half of 2022, the Group:

1. continued to participate in the “Spread the Love in Inner Mongolia, Helping Patients in Pursuit of Health and Dreams” (大愛北疆 助康圓夢) charity campaign jointly organized by the Inner Mongolia Disabled Persons’ Federation and Inner Mongolia Disabled Persons’ Welfare Foundation to provide examination and treatment to children suffering from amblyopia;
2. continued to participate in the “Belt and Road: Bright Tour” project and conduct free cataract screening and cataract recovery operations in both Inner Mongolia Autonomous Region and Mongolia;
3. provided free optical screening events and established medical profiles for primary and secondary school students in Inner Mongolia;
4. provided professional and customized rehabilitation trainings for children with low vision and squint and prevention activities to educate children and parents for early diagnosis;
5. conducted various forms of online and offline expert science lectures on eye health for students and their parents to enrich their knowledge in eye health and common eye diseases among children; and
6. led 10 scientific research projects with various authorities and published six articles on reputable scientific journals.

Overcoming Challenges Posed by COVID-19 Pandemic

The novel coronavirus (COVID-19) pandemic has spread globally and has adversely affected the global economy. The Group's business is currently facing a temporary impact from the COVID-19 pandemic as patients are unable to receive their scheduled treatments from the Group's ophthalmic hospitals and optical centers in time due to pandemic prevention policies as implemented by the local governments.

In line with the PRC Government's measures and requirements to contain the pandemic, and to protect the Group's employees and customers from infection, the Group has taken various precautionary measures at its hospitals and optical centers in response to the COVID-19 outbreak, including (i) setting up strict entrance registration and temperature screening procedures for the Group's patients and customers; (ii) limiting the number of patients and customers in our hospitals and optical centers at the same time; (iii) reducing the density of personnel in the Group's hospitals and optical centers; (iv) requiring nucleic acid PCR testing for the Group's patients before they receive surgeries or other in-patient services; (v) establishing nucleic acid PCR testing laboratories and activities and developing nucleic acid PCR testing services to ensure the safety of employees resuming work; (vi) actively participate in local COVID-19 prevention works and send medical professionals to various COVID-19 testing spots to support nucleic acid PCR testing; and (vii) maintaining continuous and effective communication with the patients and ensure that the patients visit the hospital in a timely manner during the COVID-19 pandemic.

OUTLOOK AND FUTURE

The demand for ophthalmic medical services has grown steadily in recent years and is expected to experience relatively high growth rates in the foreseeable future as a result of continued economic growth and an increasingly aging population, according to Frost & Sullivan. The size of China's ophthalmic medical services market increased from RMB73.0 billion in 2015 to RMB127.5 billion in 2019, representing a CAGR of 15.0%, and is expected to further reach RMB223.1 billion by 2024. In particular, the size of ophthalmic medical services market in North China increased from RMB13.2 billion in 2015 to RMB21.2 billion in 2019, representing a CAGR of 12.5%, and is expected to further grow to RMB33.7 billion by 2024. However, ophthalmic medical resources in China are scarce, and the penetration rate of surgeries for eye diseases in China is low.

Tumote Youqi Chaoju Eye Hospital Co., Ltd.* (土默特右旗朝聚眼科醫院有限公司) has obtained the necessary licenses and subsequently commenced business in July 2022 and Hangzhou Chaoju Eye Hospital Co., Ltd.* (杭州朝聚眼科醫院有限公司) (formerly known as Hangzhou Chaoju Optometry Hospital Co., Ltd.* (杭州朝聚眼視光醫院有限公司)) has obtained the necessary licenses and subsequently commenced business in August 2022. As of the date of this report, the Group operated a network of 20 ophthalmic hospitals and 25 optical centers. The Group plans to continue expanding its layout in Zhejiang Province and expects hospitals established in Zhoushan and other places to commence business in the second half of 2022.

As a leading ophthalmic medical services group in China, the Group is able to leverage on its branding and market reputation in North China, and continue to increase its market share in North China. The Group has further enhanced its brand awareness and reputation in East China through continuously acquiring hospitals and optical centers in East China to expand its market share and consolidate the Group's market position in the region. The Group is well-positioned to capture the significant growth potential of the underserved market of private ophthalmic services in China.

Management Discussion and Analysis

Looking into the future, the Group expects to:

- (1) adhere to the vision of “Being a Leader of Happy Ophthalmic Healthcare” to provide effective medical services and continuously revising its improvement plans;
- (2) reinforce its leading position in North China and enhance its market positioning in Zhejiang Province and other key regions while developing its featured ophthalmic hospitals;
- (3) seize opportunities in the consumer ophthalmic market to become a national chain provider of ophthalmic services trusted by the public;
- (4) improve the utilization efficiency of its regional resources and strengthen its centralized management model with regional center hospitals as the core;
- (5) serve with quality medical services and continuously improve patient satisfaction and brand awareness;
- (6) actively attract and recruit talents by further refining its training and career development programs, cultivating its unique corporate culture and offering fair incentives to its key employees; and
- (7) standardize the management of the Group and the communication with regulatory authorities, such as the Stock Exchange, and various professional institutions, so as to improve the comprehensive corporation governance.

FINANCIAL REVIEW

Revenue

The Group generates revenue primarily from (i) consumer ophthalmic services and (ii) basic ophthalmic services. The revenue of the Group increased by 6.5% from RMB500.2 million for the six months ended June 30, 2021 to RMB532.7 million for the six months ended June 30, 2022.

Consumer ophthalmic services

The Group’s consumer ophthalmic services include treatments and prevention of various types of ophthalmic disorders, including refractive correction (including presbyopia correction), myopia control and provision of optical products and services.

The Group’s revenue from consumer ophthalmic services increased by 9.2% from RMB266.5 million for the six months ended June 30, 2021 to RMB291.1 million for the six months ended June 30, 2022, primarily due to (i) implementing and further optimizing effective marketing promotional methods with focus on online promotion activities; (ii) maintaining customer loyalty through optimizing the customer membership management model; and (iii) reinforcing training to the professionals on consumer ophthalmic techniques and related skills, implementing stringent quality control, and providing quality medical services to improve the reputation of the Group.

Basic ophthalmic services

The Group's basic ophthalmic services include treatments of a wide range of common eye diseases, including cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases and pediatric eye diseases.

The Group's revenue from basic ophthalmic services increased by 3.7% from RMB233.0 million for the six months ended June 30, 2021 to RMB241.7 million for the six months ended June 30, 2022, primarily due to (i) increasing marketing initiatives; (ii) increasing investments and usage of advance and high-end medical equipment; and (iii) strengthening medical quality control that improved the branding and reputation of the Group, which attracted more patients to receive treatment for basic eye diseases at the ophthalmic hospitals of the Group, and in particular, there was an increasing amount of patients who chose to return and receive treatment for their other eye.

Cost of Sales

During the Reporting Period, the Group's cost of sales was primarily composed of medical consumables and optical products, employee compensation directly related to our provision of medical services, cost of pharmaceuticals, depreciation, amortization and rental expenses.

The Group's cost of sales increased by 5.7% from RMB272.8 million for the six months ended June 30, 2021 to RMB288.4 million for the six months ended June 30, 2022, which is in line with the increase in revenue.

Gross Profit and Gross Profit Margin

The Group's gross profit increased by 7.4% from RMB227.4 million for the six months ended June 30, 2021 to RMB244.3 million for the same period in 2022.

The Group's gross profit margin increased from 45.5% for the six months ended June 30, 2021 to 45.9% for the six months ended June 30, 2022. The increase in gross profit margin was primarily due to (i) the effects of economies of scale that resulted in dilution of related costs; and (ii) consumer ophthalmic services having a higher gross profit margin compared to basic ophthalmic services and the revenue contribution of consumer ophthalmic services increased compared to the same period last year, which increased the overall gross profit margin.

Other Income and Gains

During the Reporting Period, the Group's other income and gains were primarily composed of interest income, fair value gains, exchange gains and government grants.

The Group's other income and gains increased by 441.7% from RMB3.6 million for the six months ended June 30, 2021 to RMB19.5 million for six months ended June 30, 2022, primarily due to (i) an increase in interest income derived from the matured subscriptions of structured deposit products being recognized as fair value gains on financial assets at fair value through profit or loss; and (ii) an increase in interest income derived from the Group's bank balances resulting from inflow of the IPO Proceeds.

Management Discussion and Analysis

Selling and Distribution Expenses

During the Reporting Period, the Group's selling and distribution expenses were primarily composed of the compensation of the Group's sales and marketing personnel and advertising expenses, depreciation, amortization, office expenses and rental expenses.

The Group's selling and distribution expenses increased by 28.9% from RMB20.4 million for the six months ended June 30, 2021 to RMB26.3 million for the six months ended June 30, 2022, primarily due to (i) an increase in labor expenses due to the expansion of the Group's sales and marketing team; and (ii) an increase in marketing and advertising expenses, which was due to an increase in the investment of online promotion, new media and other online channels and also an increase in marketing initiatives in North China and East China.

Administrative Expenses

During the Reporting Period, the Group's administrative expenses were primarily composed of the compensation of and share-based payments to the Group's administrative and management personnel, depreciation and amortization, rental expenses and fees paid for the professional services and listing expenses incurred in connection with the Global Offering and office expenses.

The Group's administrative expenses decreased by 0.6% from RMB93.3 million for the six months ended June 30, 2021 to RMB92.7 million for the six months ended June 30, 2022, primarily due to the recognition of non-recurring listing expenses of approximately RMB18.3 million for the six months ended June 30, 2021 while no such expenses were recognized for the six months ended June 30, 2022 and such decrease was partially offset by an increase in expenses incurred at an early stage of establishment of Hohhot No.2 Hospital, Hangzhou Chaoju Eye Hospital Co., Ltd.* (杭州朝聚眼科醫院有限公司) (formerly known as Hangzhou Chaoju Optometry Hospital Co., Ltd.* (杭州朝聚眼視光醫院有限公司)), Zhoushan Chaoju Eye Hospital Co., Ltd.* (舟山朝聚眼科醫院有限公司) and Tumote Youqi Chaoju Eye Hospital Co., Ltd.* (土默特右旗朝聚眼科醫院有限公司) (collectively referred as to the "New Hospitals").

Impairment Losses on Financial Assets

During the Reporting Period, the Group's impairment losses on financial assets were primarily composed of provision for impairment losses on trade receivables, and other receivables.

The Group's impairment losses on financial assets increased by 23.4% from RMB4.7 million for the six months ended June 30, 2021 to RMB5.8 million for the six months ended June 30, 2022, primarily due to an increase in the non-recurring impairment losses on accounts receivables and other receivables due from third parties.

Finance Costs

During the Reporting Period, the Group's finance costs were primarily composed of interest expenses on lease liabilities.

The Group's finance costs increased by 24.4% from RMB4.5 million for the six months ended June 30, 2021 to RMB5.6 million for the six months ended June 30, 2022, primarily due to an increase in interest expenses on lease liabilities, resulted from financing the lease payments in respect of the premises of the New Hospitals which commenced business in the first half of 2022 or will be commencing business in the second half of 2022.

Income Tax Expense

During the Reporting Period, the income tax rate generally applicable to the Group's subsidiaries in China is 25% and certain of the Group's subsidiaries are eligible for a preferential income tax rate of 15%. Certain other subsidiaries are eligible for a preferential income tax rate of 2.5% or 5% with respect to part of their taxable income.

The Group's income tax expense increased by 8.1% from RMB27.3 million for the six months ended June 30, 2021 to RMB29.5 million for the six months ended June 30, 2022, primarily due to an increase in the Group's profit before tax.

Net Profit and Non-IFRS Adjusted Net Profit

As a result of the foregoing, the Group's net profit increased by 29.4% to RMB101.8 million for the six months ended June 30, 2022 from RMB78.7 million for the same period in 2021. The Group's net profit margin increased to 19.1% for the six months ended June 30, 2022 from 15.7% for the same period in 2021. The Group defined non-IFRS adjusted net profit as profit for the period adjusted for items which are non-recurring or extraordinary, including share-based compensation expenses. The Group's non-IFRS adjusted net profit increased by 4.8% to RMB103.3 million for the six months ended June 30, 2022 from RMB98.6 million for the same period in 2021.

Non-IFRS Measures

To supplement the Group's condensed consolidated financial statements which are presented in accordance with IFRS, the Company has provided non-IFRS adjusted net profit and non-IFRS adjusted net profit margin as non-IFRS measures, which are not required by, or presented in accordance with, IFRS. The Company believes that the non-IFRS adjusted financial measures provide useful information to investors and others in understanding and evaluating the Group's condensed consolidated statements of profit or loss in the same manner as they helped the Company's management, and that the Company's management and investors may benefit from referring to these non-IFRS adjusted financial measures in assessing the Group's operating performance from period to period by eliminating impacts of items that the Group does not consider indicative of the Group's operating performance. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view the non-IFRS adjusted results on a stand-alone basis or as a substitute for results under IFRS.

Management Discussion and Analysis

The following table sets forth the reconciliations of the Group's non-IFRS financial measures for the six months ended June 30, 2021 and 2022 to the nearest measures prepared in accordance with IFRS:

	Six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Net Profit	101,761	78,671
Adjustments:		
Listing expenses (after tax)	–	13,695
Share-based compensation expenses	1,489	6,240
Non-IFRS adjusted net profit⁽¹⁾	103,250	98,606
Non-IFRS adjusted net profit margin⁽²⁾	19.4%	19.7%

Notes:

- (1) Non-IFRS adjusted net profit was calculated as net profit for the Reporting Period excluding share-based compensation expenses.
- (2) Non-IFRS adjusted net profit margin was calculated based on non-IFRS adjusted net profit divided by revenue.

Financial Position

Trade Receivables

The Group's trade receivables increased by 20.3% from RMB54.2 million as of December 31, 2021 to RMB65.2 million as of June 30, 2022, primarily due to an increase in receivables from medical insurance.

Prepayments, other receivables and other assets

The Group's prepayments, other receivables and other assets mainly include prepayments and deposits. Prepayments, other receivables and other assets increased by 59.1% from RMB47.4 million as of December 31, 2021 to RMB75.4 million as of June 30, 2022, primarily due to an increase in prepayments for the purchase of advance medical equipment (including Visumax).

Liquidity and Capital Resources

The business operations and expansion plans of the Group require a significant amount of capital, including the relocation, upgrading and renovation of the existing in-network hospitals, the establishment and acquisition of new hospitals and other working capital requirement. The Group financed its capital expenditures and other working capital requirements mainly through cash generated from its operations and cash generated from its financing activities including the proceeds that the Group received from the Global Offering in July 2021. As of June 30, 2022, the Group had cash and cash equivalents of RMB1,414.4 million.

Capital Structure

The Shares of the Company were listed on the Main Board of the Stock Exchange on July 7, 2021, and 137,500,000 Shares of the Company were issued at the offer price of HK\$10.60 per Share by way of the Global Offering. Subsequently, the Company announced that the over-allotment option described in the Prospectus was partially exercised on July 29, 2021, in respect of an aggregate of 20,125,000 Shares. There was no changes in the capital structure of the Group since then. The share capital of the Group only comprises ordinary shares. As of June 30, 2022, the total issued share capital of the Company was HKD380,000 divided into 1,520,000,000 shares.

The capital structure of the Group was 15.4% debt and 84.6% equity as of June 30, 2022, compared with 15.1% debt and 84.9% equity as of December 31, 2021.

Cash and Bank Balances

The Group's business operations and expansion plans require significant amount of capital, which will be used for upgrading the existing ophthalmic hospitals and optical centers, establishing and acquiring new hospitals and other working capital requirements. The Group's principal sources of liquidity are cash generated from its business operations, as well as debt and equity financing.

	Six months ended June 30,	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Net cash flows from operating activities	156,703	127,250
Net cash flows from investing activities	71,990	(14,377)
Net cash flows from financing activities	(100,888)	(88,028)
Effect of foreign exchange rate changes, net	29,483	93
Net increase in cash and cash equivalents	157,288	24,938

The Group's net increase in cash and cash equivalents is RMB157.3 million for the six months ended June 30, 2022, primarily due to net cash inflows of RMB156.7 million from operating activities and net cash inflows of RMB72.0 million from investment activities, which was mainly due to net subscriptions and redemptions of structured deposit products in an amount of RMB168.6 million, which was partially offset by net cash outflows of RMB100.9 million from financing activities, resulting from the payment of dividends in an amount of RMB62.7 million.

Trade Payables

The Group's trade payables increased by 61.7% from RMB36.8 million as of December 31, 2021 to RMB59.5 million as of June 30, 2022, primarily due to an increase in payables for medical consumables and pharmaceuticals.

Other Payables and Accruals

The Group's other payables and accruals include salaries and welfare payables, rent payables, payables for purchases of property, plant and equipment and contract liabilities.

The Group's other payables and accruals increased by 6.1% from RMB121.4 million as of December 31, 2021 to RMB128.8 million as of June 30, 2022, primarily due to an increase in the salaries and welfare payables from the increased number of employees and contract liabilities.

Management Discussion and Analysis

Contingent Liabilities

As of June 30, 2022, the Group did not have any material contingent liabilities or guarantees.

Pledge of Assets

As of June 30, 2022, no asset has been pledged by the Group (as of December 31, 2021: nil).

Capital Commitments

As of June 30, 2022, the Group had a total capital commitment of approximately RMB10.8 million (as of December 31, 2021: RMB21.8 million), primarily related to the construction and renovation of its in-network hospitals.

Borrowings and Gearing Ratio

As of June 30, 2022, the Group is in a net cash position and thus, gearing ratio is not applicable.

Interest Rate Risk

The Group's interest rate risk arises from interest-bearing borrowings. Borrowings issued at fixed rates expose the Group to fair value interest rate risk. Borrowings issued at variable rates expose the Group to cash flow interest rate risk. The Group currently does not use any interest rate swap contracts or other financial instruments to hedge against interest rate exposure.

Credit Risk

Credit risk is the risk regarding the loss arising from a counterparty's inability to meet its obligations. The management of the Group has put in place a credit policy and the exposure to such credit risks is monitored on an on-going basis.

Liquidity Risk

The Group's liquidity is primarily dependent on our ability to maintain adequate cash inflows from operations to meet its debt obligations as they fall due, and the ability to obtain external financing to meet its committed future capital expenditure.

The Group monitors and maintains a level of cash and cash equivalents deemed adequate by its management to finance the operation and mitigate the effects of fluctuations in cash flows.

Foreign Currency Risk

Foreign currency risk refers to the risk of loss resulting from changes in foreign currency exchange rates. Fluctuations in exchange rates between RMB and other currencies in which the Group conducts business may affect our financial condition and results of operation. The Group mainly operates in the PRC and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to Hong Kong dollars. The conversion of foreign currencies into RMB, including Hong Kong dollars, has been based on rates set by the People's Bank of China. The Group seeks to limit our exposure to foreign currency risk by closely monitoring and minimizing its net foreign currency position. During the Reporting Period, the Group did not enter into any currency hedging transactions.

Interim Dividends

The Board has resolved not to declare any dividends for the six months ended June 30, 2022.

Significant Investments

The Group subscribed for low-risk short-term structured deposit products issued by reputable commercial banks with certain portion of its temporary idle funds (including surplus cash received from its business operations and idle IPO Proceeds) for treasury management purpose in order to enhance the efficiency, the utilization of and the return on its temporary idle funds. These products are of very low risk nature with satisfactory liquidity and the Group expects that the structured deposit products will earn a better yield than current deposits generally offered by commercial banks in the PRC while at the same time offer flexibility to the Group in terms of treasury management. The Group has implemented adequate and appropriate internal control procedures to ensure subscriptions of structured deposit products would not affect the working capital or the operations of the Group, and that such investments would be closely monitored and conducted in accordance with the Group's treasury policy. As such, the Board is of the view that the subscriptions of the structured deposit products (as listed below) are fair and reasonable, and are on normal commercial terms and the subscriptions are in the interests of the Company and the Shareholders as a whole.

For the year ended December 31, 2021, the Group subscribed for structured deposit products in a principal amount of RMB520 million offered by BOC and ICBC, details of which are as follows:

Name of the issuer of the structured deposit products	Name of the structured deposit products	Date of subscription	Deposit starting date	Date of maturity	Principal amount of subscription (RMB'000)	Expected annualized return rate ⁽¹⁾	Realized/ Unrealized gains or (losses) as of December 31, 2021 (RMB'000)	Fair value as of December 31, 2021 (RMB'000)	Investment Scope	Percentage of the total assets of the Group as of December 31, 2021
BOC	BOC Linked Structured Deposit Product (Corporate Client) (中國銀行掛鈎型結構性存款) (機構客戶) (CSDVY202109218)	November 17, 2021	November 19, 2021	February 17, 2022	130,000*	1.5000% to 4.5492%	267	130,267	This structured deposit product is linked structural deposit. The linked indicator is USD/EUR exchange rate.	5.20%
	BOC Linked Structured Deposit Product (Corporate Client) (中國銀行掛鈎型結構性存款) (機構客戶) (CSDVY202109219)	November 17, 2021	November 19, 2021	February 18, 2022	130,000*	1.5100% to 4.5417%	12	130,012	This structured deposit product is linked structural deposit. The linked indicator is USD/EUR exchange rate.	5.19%
ICBC	ICBC Linked Exchange Rate Interval Accumulative Corporate RMB Structured Deposit Product - Designated Account 2021 No. 362 Type C (中國工商銀行掛鈎匯率區間累計型法人民幣結構性存款產品-專戶型2021年第362期C款)	December 10, 2021	December 13, 2021	March 15, 2022	260,000 [#]	1.3000% to 2.5000%	(236)	259,764	This structured deposit product is linked structural deposit. The linked indicator is USD/JPY exchange rate.	10.36%

Notes:

(1) Upon maturity, the Group expects to get back the principal amount together with the expected interest.

* This subscription amount was funded by surplus cash of the Group.

[#] This subscription amount was funded by the idle IPO Proceeds.

Management Discussion and Analysis

As of June 30, 2022, the abovementioned products have reached their maturity. The total amount of the actual interest received from the matured structured deposit products (CSDVY202109218 and CSDVY202109219) subscribed with BOC on November 17, 2021 was RMB1,952,830.44 and the total amount of the actual interest received from the matured structured deposit product subscribed with ICBC on December 10, 2021 was RMB1,638,356.16.

As of June 30, 2022, the Group maintained a portfolio of structured deposit products with a total outstanding principal amount of RMB360.0 million, and the size of structured deposit products subscribed by the Group in aggregate represented approximately 13.9% of the Group's total assets. For the six months ended June 30, 2022, the total principal amount of the structured deposit products that the Group has subscribed for was RMB1.1 billion and the amount of interest income that the Group has recognized as fair value gains on financial assets at fair value through profit or loss was approximately RMB9.5 million.

The following table sets forth a breakdown of the major structured deposit products subscribed by the Group as of June 30, 2022.

Name of the issuer of the structured deposit products	Name of the structured deposit products	Date of subscription	Deposit commencement date	Date of maturity	Principal amount of subscription (RMB'000)	Expected annualized return rate ⁽¹⁾	Realized/ Unrealized gains or (losses) as of June 30, 2022 (RMB'000)	Realized/ Fair value as of June 30, 2022 Investment scope (RMB'000)		Percentage of the total assets of the Group as of June 30, 2022
BOC	BOC Linked Structured Deposit Product (Corporate Client) (中國銀行掛鉤型結構性存款) (機構客戶) (CSDVY202212975)	February 21, 2022	February 22, 2022	May 23, 2022	130,100*	1.5400% to 4.8300%	1,344	131,444	This structured deposit product is linked structural deposit. The linked indicator is USD/EUR exchange rate.	5.06%
	BOC Linked Structured Deposit Product (Corporate Client) (中國銀行掛鉤型結構性存款) (機構客戶) (CSDVY202212976)	February 21, 2022	February 22, 2022	May 23, 2022	129,900*	1.5300% to 4.8200%	694	130,594	This structured deposit product is linked structural deposit. The linked indicator is USD/EUR exchange rate.	5.03%
ICBC	ICBC Linked Exchange Rate Interval Accumulative Corporate RMB Structured Deposit Product – Designated Account 2022 No. 104 Type A (中國工商銀行掛鉤匯率區間累計型法人人民幣結構性存款產品—專戶型2022年第104期A款)	March 17, 2022	March 21, 2022	June 23, 2022	260,000 [†]	1.3000% to 3.1200%	1,146	261,146	This structured deposit product is linked structural deposit. The linked indicator is USD/JPY exchange rate.	10.05%

Name of the issuer of the structured deposit products	Name of the structured deposit products	Date of subscription	Deposit commencement date	Date of maturity	Principal amount of subscription (RMB'000)	Expected annualized return rate ⁽¹⁾	Realized/ Unrealized gains or (losses) as of June 30, 2022 (RMB'000)	Realized/ Fair value as of June 30, 2022 (RMB'000)	Investment scope	Percentage of the total assets of the Group as of June 30, 2022
BOC	BOC Linked Structured Deposit Product (Corporate Client) (中國銀行掛鉤型結構性存款) (機構客戶) (CSDVY202214220)	March 30, 2022	March 31, 2022	June 29, 2022	115,100*	1.8000% to 4.5900%	1,298	116,398	This structured deposit product is linked structural deposit. The linked indicator is USD/EUR exchange rate.	4.48%
	BOC Linked Structured Deposit Product (Corporate Client) (中國銀行掛鉤型結構性存款) (機構客戶) (CSDVY202214221)	March 30, 2022	March 31, 2022	June 29, 2022	114,900*	1.7900% to 4.5800%	511	115,411	This structured deposit product is linked structural deposit. The linked indicator is USD/EUR exchange rate.	4.44%
	BOC Linked Structured Deposit Product (Corporate Client) (中國銀行掛鉤型結構性存款) (機構客戶) (CSDVY202216535)	May 25, 2022	May 26, 2022	August 24, 2022	129,900 [#]	1.5400% to 4.6500%	192	130,092	This structured deposit product is linked structural deposit. The linked indicator is EUR/USD exchange rate	5.01%
	BOC Linked Structured Deposit Product (Corporate Client) (中國銀行掛鉤型結構性存款) (機構客戶) (CSDVY202216536)	May 25, 2022	May 26, 2022	August 24, 2022	130,100 [#]	1.5300% to 4.6400%	191	130,291	This structured deposit product is linked structural deposit. The linked indicator is EUR/USD exchange rate	5.01%

Notes:

(1) Upon maturity, the Group expects to receive the principal amount together with the expected interest.

* This subscription amount was funded by surplus cash of the Group.

[#] This subscription amount was funded by the idle IPO Proceeds.

Save as disclosed in this report, there was no other significant investments held by the Group during the Reporting Period.

Management Discussion and Analysis

Material Acquisitions and Disposals

The Group did not have any material acquisitions or disposals of subsidiaries, consolidated affiliated entities or associated companies during the six months ended June 30, 2022.

Future Plan for Material Investment and Capital Asset

Save as disclosed in this report and the Prospectus of the Company, the Group did not have any future plan for material investments and capital assets.

EMPLOYEES AND REMUNERATION POLICIES

As of June 30, 2022, the Group had 1,863 full-time employees, among which, 1,015 were professionals at the hospitals, 93 were professionals at the optical centers and 755 were administrative, finance and other employees at the Group's headquarters, hospitals and optical centers. In addition, the Group also had 77 multi-site practice physicians who were full-time employees of other medical institutions. The following table shows a breakdown of the Group's full-time employees by function as of that date:

	As of June 30, 2022	
	Number of employees	% of total employees
Professionals at the hospitals		
Physicians ⁽¹⁾	207	11.11%
Nurses	449	24.10%
Other professionals	359	19.27%
Professionals at the optical centers	93	4.99%
Administrative, finance and other employees at		
The headquarters	110	5.90%
The hospitals	581	31.19%
The optical centers	64	3.44%
Total	1,863	100%

Note:

(1) As of June 30, 2022, 178 of the full-time physicians were registered as specialized ophthalmologists.

The Group enters into employment contracts with all of its full-time employees. The remuneration packages for its employees primarily comprise one or more of the following elements: basic salary, performance-based incentive bonus and discretionary year-end bonus. The Group also sets performance targets for its employees based on their position and regularly reviews their performance, the results of which are used in their annual salary review and promotion appraisal.

The Group adopted a share award scheme on May 10, 2022, for the purposes of incentivizing certain employees of the Group and attracting talents for the development of the Group. The Scheme does not constitute a share option scheme pursuant to Chapter 17 of the Listing Rules and no Shareholders' approval is required for the adoption or implementation of the Scheme. The Group has not granted any award shares since the adoption of the Scheme and up to June 30, 2022. For further information, please refer to the announcement of the Company dated May 10, 2022.

The Group provides structured training and education programs which enables its employees to consistently deliver high quality services. The Group's discipline development committees are responsible for training its medical professionals, maintaining a proper mix of different levels of professionals, as well as research and development, and have supplied numerous young ophthalmologists with solid skills and rich clinical experience. The Group also engages external consultants, experts and professors to provide trainings for the physicians with an aim to cultivate clinicians with extensive practical capabilities in a precise, standardized and high-quality manner. These programs aim to equip them with a sound foundation of the medical principles, ethics and knowledge as well as practical skills, and foster a high standard of practice. Regular internal and external mandatory online and on-site trainings are organized for the medical team to keep them abreast of the latest development in the ophthalmology industry. From time to time, the Group identifies and sponsors its employees with high development potential to undertake further study and professional trainings in prestigious medical institutions. They also support their attending physicians to train at top-tier eye hospitals in China for a period of three to six months, such as Wenzhou Medical University Eye Hospital (溫州醫科大學附屬眼視光醫院). In addition, the Group also designs and implements specialized trainings for its nurses and medical assistants to improve their respective professional skills and foster their professional career path.

As of June 30, 2022, none of the Group's employees had negotiated with them on the employment terms through the labor unions or in a way of collective bargaining and the Group had not experienced any major labor disputes or labor strikes that had interfered with its operations in any material respect.

Other Information

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

Since January 1, 2022 and up to the date of this report, save as provisions addressed below, the Company has complied with all the applicable code provisions as set out in the Corporate Governance Code contained in Appendix 14 to the Listing Rules.

Code provision C.2.1 of the Corporate Governance Code stipulates that the roles of chairman and chief executive should be separate and should not be performed by the same individual.

The roles of chairman of the Board and chief executive officer of the Company are held by Mr. Zhang Bozhou who has extensive experience in the industry. The Board believes that vesting the roles of the chairman and chief executive officer in Mr. Zhang Bozhou is beneficial to the management of the Group and will improve the efficiency of the Group's decision making and executive process given his knowledge in the Group's affairs. Further, the Group has put in place an appropriate check-and-balance mechanism through the Board and the independent non-executive Directors.

In view of the above, the Board considers that such structure will not impair the balance of power and authority between the Board and the management of the Group. The Board will review the corporate governance structure and practices from time to time and shall make necessary arrangement when the Board considers appropriate.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the “**Model Code**”) as set out in Appendix 10 of the Listing Rules as its code of conduct regarding securities transactions by the Directors. Upon specific enquiry, all Directors confirmed that they had complied with the requirements as set out in the Model Code since January 1, 2022 and up to the date of this report.

PURCHASE, SALE OR REDEMPTION OF THE LISTED SECURITIES OF THE COMPANY

Since January 1, 2022 and up to the date of this report, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities.

AUDIT COMMITTEE

The Company has established the Audit Committee with written terms of reference in compliance with the requirements under the Listing Rules. The Audit Committee is composed of three independent non-executive Directors, being Mr. Li Jianbin (chairman of the Audit Committee), Ms. Guo Hongyan and Mr. Bao Shan. The primary duties of the Audit Committee are to assist the Board in providing an independent view of the effectiveness of the financial reporting process, the internal control and risk management system of the Group, to oversee the audit process and to perform other duties and responsibilities as assigned by the Board.

REVIEW OF INTERIM REPORT

The independent auditors of the Company, namely Ernst & Young, have carried out a review of the interim financial information in accordance with the Hong Kong Standard on Review Engagement 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Hong Kong Institute of Certified Public Accountants. The Audit Committee has jointly reviewed with the management and the independent auditors of the Company, the accounting principles and policies adopted by the Company and discussed internal control and financial reporting matters (including the review of the unaudited interim results for the six months ended June 30, 2022) of the Group. The Audit Committee and the independent auditors considered that the interim results are in compliance with the applicable accounting standards, laws and regulations, and the Company has made appropriate disclosures thereof.

CHANGES TO DIRECTORS' INFORMATION

As of June 30, 2022, there were no changes in the Directors' information which are required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

PROCEEDS FROM GLOBAL OFFERING AND ITS UTILIZATION

The Company issued 137,500,000 Shares in the Global Offering at HK\$10.60 per Share which were listed on the Main Board of the Stock Exchange on July 7, 2021 and subsequently issued 20,125,000 Shares at HK\$10.60 per Share on August 3, 2021 upon partial exercise of the over-allotment option.

The net proceeds from the Global Offering received by the Company, after deduction of the underwriting fees and commissions and other expenses payable by the Company in connection with the Global Offering, amounted to approximately HK\$1,599 million, which will be utilized in accordance with the purposes as set out in the Prospectus. The following table sets out the planned applications of the net proceeds as well as the expected timeline for utilization:

	Percentage of the net proceeds from the Global Offering	Net proceeds from the Global Offering HK\$ million	Amount utilized as of June 30, 2022 HK\$ million	Unutilized amount as of June 30, 2022 HK\$ million	Expected timeline for utilization ⁽¹⁾
Establishment of new hospitals and the relocation, upgrade and renovation of existing hospitals	35.8%	572.4	101.9	470.5	From July 2021 to June 2024
Acquiring hospitals, when appropriate opportunities arise, in new markets with sizable population and relatively high level of demand for ophthalmic healthcare services	44.8%	716.4	12.0	704.4	From July 2021 to December 2023
Upgrading information technology systems	9.4%	150.3	11.7	138.6	From July 2021 to December 2023
Working capital and other general corporate purposes	10.0%	159.9	156.8	3.1	From July 2021 to December 2023
Total	100%	1,599	282.4	1,316.6	

Note:

- (1) The expected timeline for utilization was based on the best estimation of the future market conditions made by the Group. It will be subject to change based on the current and future development of market conditions.

As stated in the announcement of the Company dated November 17, 2021 in relation to the (1) discloseable transactions of subscriptions of the November Structured Deposit Products and (2) utilization of certain idle proceeds raised from the Global Offering for treasury management, with a view to enhancing the utilization and efficiency of its idle IPO Proceeds, the Company intends to apply and has applied some of the idle IPO Proceeds to further subscribe for low-risk short-term wealth management products issued by reputable commercial banks similar to the subscriptions of the November Structured Deposit Products in the PRC or Hong Kong in the future, thereby increasing the overall income of the Company while at the same time ensuring that the planned usage of IPO Proceeds will not be affected. For further information, please refer to the announcements of the Company dated March 17, 2022 and May 25, 2022.

Other Information

EVENTS AFTER THE REPORTING PERIOD

Since July 1, 2022 and up to the date of this report, the Group subscribed for structured deposit products in the principal amount of RMB490 million in total offered by BOC. For further information, please refer to the announcements of the Company dated June 30, 2022 and August 25, 2022.

Save as disclosed above, there was no significant event that might affect the Group after the Reporting Period.

INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ITS ASSOCIATED CORPORATIONS

(i) Interests and short positions of the Directors and the chief executive of the Company in the Shares, and underlying Shares and debentures of the Company and its associated corporations

As of June 30, 2022, the interests or short positions of the Directors or chief executives in the Shares, underlying Shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which will be required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO) or which will be required, under Section 352 of the SFO, to be entered in the register referred to in that section, or which will be required, under the Model Code, once the Shares are listed will be as follows:

Interest in Shares or Underlying Shares of the Company

Name of Director	Nature of interest	Number of Shares or underlying Shares	Approximate percentage of shareholding interest
Mr. Zhang Bozhou	Interests held jointly with another person; interests of controlled corporation	286,457,000	40.48%
Ms. Zhang Xiaoli	Interests held jointly with another person; interests of controlled corporation	286,457,000	40.48%
Mr. Zhang Junfeng	Interests held jointly with another person; interests of controlled corporation	286,457,000	40.48%
Ms. Zhang Wenwen	Interests of controlled corporation	36,465,000	5.15%

(ii) Interests in the Company's associated corporations

So far as the Directors are aware, as of June 30, 2022, the following persons were interested in 10% or more of the nominal value of the share capital carrying rights to vote in all circumstances at general meetings of any member of the Group (other than the Company):

Name of Director	Name of member of the Group	Approximate percentage of shareholding
Mr. Zhang Bozhou	Xiamen Xinkangnuo	26.64%
Ms. Zhang Xiaoli	Xiamen Xinkangnuo	29.03%
Mr. Zhang Junfeng	Xiamen Xinkangnuo	20.67%

Director's Rights to Acquire Shares on Debentures

Save as otherwise disclosed in this report, at no time during the Reporting Period was the Company or any of its subsidiaries a party to any arrangement that would enable the Directors to acquire benefits by means of acquisition of shares in, or debentures of, the Company or any other body corporate, and none of the Directors or any of their spouses or children under the age of 18 were granted any right to subscribe for the equity or debt securities of the Company or any other body corporate or had exercised any such right.

INTERESTS AND SHORT POSITIONS OF THE SUBSTANTIAL SHAREHOLDERS IN SHARES AND UNDERLYING SHARES OF THE COMPANY

So far as the Directors are aware, as of June 30, 2022, the following persons had an interest or a short position in the Shares which would be required to be disclosed to the Company and the Stock Exchange pursuant to the provisions of Division 2 and 3 of Part XV of the SFO or were, directly or indirectly, interested in 5% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of the Company:

Name of Shareholder	Nature of interest	Number of Shares/ underlying Shares	Approximate percentage of shareholding interest in the Company	Long position/ Short position/ Lending pool
Mr. Zhang Bozhou ⁽¹⁾⁽²⁾	Interests held jointly with another person; interests of controlled corporation	286,457,000	40.48%	Long position
Ms. Zhang Xiaoli ⁽¹⁾⁽³⁾	Interests held jointly with another person; interests of controlled corporation	286,457,000	40.48%	Long position
Mr. Zhang Junfeng ⁽¹⁾⁽⁴⁾	Interests held jointly with another person; interests of controlled corporation	286,457,000	40.48%	Long position
Mr. Zhang Fengsheng ⁽¹⁾⁽⁵⁾	Interests held jointly with another person; interests of controlled corporation	286,457,000	40.48%	Long position
Ms. Zhang Yumei ⁽¹⁾⁽⁶⁾	Interests held jointly with another person; interests of controlled corporation	286,457,000	40.48%	Long position

Other Information

Name of Shareholder	Nature of interest	Number of Shares/ underlying Shares	Approximate percentage of shareholding interest in the Company	Long position/ Short position/ Lending pool
Ms. Zhang Hongbo ⁽⁷⁾	Interests of spouse	286,457,000	40.48%	Long position
Mr. He Yong ⁽⁸⁾	Interests of spouse	286,457,000	40.48%	Long position
Ms. Su Yuqin ⁽⁹⁾	Interests of spouse	286,457,000	40.48%	Long position
Ms. Li Furong ⁽¹⁰⁾	Interests of spouse	286,457,000	40.48%	Long position
Mr. Jin Longqi ⁽¹¹⁾	Interests of spouse	286,457,000	40.48%	Long position
Jutong Medical Management Co. Ltd.	Beneficial owner	77,684,000	10.98%	Long position
Sihai Medical Management Co. Ltd.	Beneficial owner	84,266,000	11.91%	Long position
Guangming Medical Management Co. Ltd.	Beneficial owner	59,966,000	8.47%	Long position
Xiamen Chaoxi Enterprise Management Consulting Partnership (Limited Partnership)* (廈門朝翕企業管理諮詢合夥企業 (有限合夥))	Beneficial owner	45,485,000	6.43%	Long position
Mr. Wang Hui ⁽¹²⁾	Interests of controlled corporation	78,540,000	11.10%	Long position
Ms. Liu Linan ⁽¹³⁾	Interests of spouse	78,540,000	11.10%	Long position
Orchid Asia VII Global Investment Limited ⁽¹⁴⁾	Beneficial owner	68,642,000	9.70%	Long position
Ms. Lam Lai Ming ⁽¹⁴⁾	Interests of controlled corporation	68,642,000	9.70%	Long position
Mr. Gabriel Li ⁽¹⁴⁾	Interests of controlled corporation	68,642,000	9.70%	Long position
Ms. Zhang Wenwen ⁽¹⁵⁾	Interests of controlled corporation	36,465,000	5.15%	Long position
Mr. Xiao Feng ⁽¹⁶⁾	Interests of spouse	36,465,000	5.15%	Long position

Notes:

- (1) Mr. Zhang Bozhou, Ms. Zhang Xiaoli, Mr. Zhang Junfeng, Mr. Zhang Fengsheng and Ms. Zhang Yumei have entered into Acting-in-concert Agreement to acknowledge and confirm their acting-in-concert relationship in relation to the Company and irrevocably entrust Mr. Zhang Bozhou to exercise, at his discretion, their voting rights at the shareholders meetings of the Group. Under the SFO, Mr. Zhang Bozhou, Ms. Zhang Xiaoli, Mr. Zhang Junfeng, Mr. Zhang Fengsheng and Ms. Zhang Yumei are deemed to be interested in the Shares which each other has interest in.
- (2) Mr. Zhang Bozhou wholly-owns Jutong Medical Management Co. Ltd. and controls Xiamen Juludazhou Equity Investment Partnership (Limited Partnership)* (廈門聚鷺達洲股權投資合夥企業 (有限合夥)) as its general partner, which held 77,684,000 and 21,945,000 Shares, respectively as of June 30, 2022.
- (3) Ms. Zhang Xiaoli wholly-owns Sihai Medical Management Co. Ltd., which held 84,266,000 Shares as of June 30, 2022.
- (4) Mr. Zhang Junfeng wholly-owns Guangming Medical Management Co. Ltd., which held 59,966,000 Shares as of June 30, 2022.
- (5) Mr. Zhang Fengsheng wholly-owns Xiwang Medical Management Co. Ltd., which held 33,686,000 Shares as of June 30, 2022.

- (6) Ms. Zhang Yumei wholly-owns Sitong Medical Management Co. Ltd., which held 8,910,000 Shares as of June 30, 2022.
- (7) Ms. Zhang Hongbo is the spouse of Mr. Zhang Bozhou and is deemed to be interested in Mr. Zhang Bozhou's interests in the Company.
- (8) Mr. He Yong is the spouse of Ms. Zhang Xiaoli and is deemed to be interested in Ms. Zhang Xiaoli's interests in the Company.
- (9) Ms. Su Yuqin is the spouse of Mr. Zhang Junfeng and is deemed to be interested in Mr. Zhang Junfeng's interests in the Company.
- (10) Ms. Li Furong is the spouse of Mr. Zhang Fengsheng and is deemed to be interested in Mr. Zhang Fengsheng's interests in the Company.
- (11) Mr. Jin Longqi is the spouse of Ms. Zhang Yumei and is deemed to be interested in Ms. Zhang Yumei's interests in the Company.
- (12) Mr. Wang Hui controls Xiamen Chaoxi and Light Medical Limited, which held 45,485,000 and 33,055,000 Shares, respectively, as of June 30, 2022.
- (13) Ms. Liu Linan is the spouse of Mr. Wang Hui and is deemed to be interested in Mr. Wang Hui's interests in the Company.
- (14) Orchid Asia VII Global Investment Limited is owned as to 7% by Orchid Asia VII Co-Investment, Limited, which is in turn wholly-owned by Areo Holdings Limited, and 93% by Orchid Asia VII, L.P.. Orchid Asia VII, L.P. is wholly-owned by OAVII Holdings, L.P., which is in turn wholly-owned by Orchid Asia VII GP, Limited. Orchid Asia VII GP, Limited is wholly-owned by Orchid Asia V Group Management, Limited, which is in turn wholly-owned by Orchid Asia V Group Limited. Orchid Asia V Group Limited is wholly-owned by Areo Holdings Limited, which is in turn wholly-owned by Ms. Lam Lai Ming, and is controlled by Mr. Gabriel Li by virtue of his directorship there.
- (15) Ms. Zhang Wenwen controls Riverhead Capital I and Riverhead Runfeng, which held 22,440,000 and 14,025,000 Shares, respectively, as of June 30, 2022.
- (16) Mr. Xiao Feng is the spouse of Ms. Zhang Wenwen and is deemed to be interested in Ms. Zhang Wenwen's interests in the Company.

Save as disclosed above, the Directors are not aware of any person who had, as of June 30, 2022, an interest or a short position in the Shares which would be required to be disclosed to the Company and the Stock Exchange under the provisions of Division 2 and 3 of Part XV of the SFO or would be, directly or indirectly, interested in 5% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of any other member of the Group.

Independent Review Report

To the board of directors of Chaoju Eye Care Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

INTRODUCTION

We have reviewed the interim financial information set out on pages 35 to 56, which comprises the condensed consolidated statement of financial position of Chaoju Eye Care Holdings Limited (the “**Company**”) and its subsidiaries (the “**Group**”) as at 30 June 2022 and the related condensed consolidated statements of profit or loss, comprehensive income, changes in equity and cash flows for the six-month period then ended, and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 *Interim Financial Reporting* (“**IAS 34**”) issued by the International Accounting Standards Board. The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with IAS 34. Our responsibility is to express a conclusion on this interim financial information based on our review. Our report is made solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Hong Kong Institute of Certified Public Accountants. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information is not prepared, in all material respects, in accordance with IAS 34.

Ernst & Young

Certified Public Accountants

Hong Kong

29 August 2022

Interim Condensed Consolidated Statement of Profit or Loss

For the six months ended 30 June 2022

	Notes	For the six months ended 30 June	
		2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
REVENUE	4	532,742	500,171
Cost of sales		(288,406)	(272,821)
Gross profit		244,336	227,350
Other income and gains		19,460	3,615
Selling and distribution expenses		(26,258)	(20,393)
Administrative expenses		(92,687)	(93,289)
Other expenses		(2,230)	(2,135)
Impairment losses on financial assets, net		(5,786)	(4,665)
Finance costs		(5,624)	(4,472)
PROFIT BEFORE TAX	5	131,211	106,011
Income tax expenses	6	(29,450)	(27,340)
PROFIT FOR THE PERIOD		101,761	78,671
Attributable to:			
Owners of the parent		103,598	80,940
Non-controlling interests		(1,837)	(2,269)
		101,761	78,671
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT			
Basic and diluted for the period (expressed in RMB per share)	8	0.15	0.15

Interim Condensed Consolidated Statement of Comprehensive Income

For the six months ended 30 June 2022

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
PROFIT FOR THE PERIOD	101,761	78,671
OTHER COMPREHENSIVE INCOME		
Other comprehensive income that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of foreign operations	28,492	19
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	130,253	78,690
Attributable to:		
Owners of the parent	132,090	80,959
Non-controlling interests	(1,837)	(2,269)
	130,253	78,690

Interim Condensed Consolidated Statement of Financial Position

30 June 2022

	Notes	30 June 2022 RMB'000 (Unaudited)	31 December 2021 RMB'000 (Audited)
NON-CURRENT ASSETS			
Property, plant and equipment	9	342,402	305,151
Right-of-use assets		196,796	180,753
Goodwill		28,228	28,228
Intangible assets		52,153	53,818
Deferred tax assets		5,958	5,729
Long-term time deposits		10,531	–
Prepayments, other receivables and other assets		39,952	18,404
Total non-current assets		676,020	592,083
CURRENT ASSETS			
Inventories		46,607	34,900
Trade receivables	10	65,224	54,167
Prepayments, other receivables and other assets		35,386	29,021
Due from related parties	15(b)	–	19,164
Financial assets at fair value through profit or loss (“FVTPL”)		361,001	520,043
Cash and cash equivalents		1,414,424	1,257,136
Total current assets		1,922,642	1,914,431
CURRENT LIABILITIES			
Trade payables	11	59,482	36,802
Other payables and accruals		127,404	120,373
Other borrowings		5,661	5,524
Lease liabilities		34,165	40,707
Tax payable		19,691	18,423
Total current liabilities		246,403	221,829
NET CURRENT ASSETS		1,676,239	1,692,602
TOTAL ASSETS LESS CURRENT LIABILITIES		2,352,259	2,284,685

Interim Condensed Consolidated Statement of Financial Position

30 June 2022

	Notes	30 June 2022 RMB'000 (Unaudited)	31 December 2021 RMB'000 (Audited)
NON-CURRENT LIABILITIES			
Other borrowings		736	717
Lease liabilities		137,636	131,699
Deferred tax liabilities		15,037	22,867
Other payables and accruals		1,436	996
Total non-current liabilities		154,845	156,279
Net assets		2,197,414	2,128,406
EQUITY			
Equity attributable to owners of the parent			
Share capital	12	152	152
Reserves		2,176,910	2,106,065
		2,177,062	2,106,217
Non-controlling interests		20,352	22,189
Total equity		2,197,414	2,128,406

Zhang Bozhou
Director

Zhang Guangdi
Director

Interim Condensed Consolidated Statement of Changes in Equity

For the six months ended 30 June 2022

	Attributable to owners of the parent							
	Share capital	Capital reserve	Share-based	Exchange	Retained profits	Total	Non-controlling interests	Total
			payment reserve	fluctuation reserve				
RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	
At 1 January 2022 (audited)	152	1,884,678	32,907	(15,958)	204,438	2,106,217	22,189	2,128,406
Profit for the period	-	-	-	-	103,598	103,598	(1,837)	101,761
Other comprehensive income for the period:								
Exchange differences on translation of foreign operations	-	-	-	28,492	-	28,492	-	28,492
Total comprehensive income for the period	-	-	-	28,492	103,598	132,090	(1,837)	130,253
Share-based payments	-	-	1,489	-	-	1,489	-	1,489
Dividend (note 7)	-	-	-	-	(62,734)	(62,734)	-	(62,734)
At 30 June 2022 (unaudited)	152	1,884,678*	34,396*	12,534*	245,302*	2,177,062	20,352	2,197,414

* These reserve accounts comprise the consolidated reserves of RMB2,176,910,000 (31 December 2021: RMB2,106,065,000) in the interim condensed consolidated statement of financial position as at 30 June 2022.

Interim Condensed Consolidated Statement of Changes in Equity

For the six months ended 30 June 2022

	Attributable to owners of the parent							
	Share capital	Capital reserve	Share-based payment reserve	Exchange fluctuation reserve	Retained profits	Total	Non-controlling interests	Total
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
At 1 January 2021 (audited)	93	559,722	21,547	197	155,689	737,248	26,297	763,545
Profit for the period	-	-	-	-	80,940	80,940	(2,269)	78,671
Other comprehensive income for the period:								
Exchange differences on translation of foreign operations	-	-	-	19	-	19	-	19
Total comprehensive income for the period	-	-	-	19	80,940	80,959	(2,269)	78,690
Share-based payments	-	-	6,240	-	-	6,240	-	6,240
Dividend (note 7)	-	-	-	-	(113,000)	(113,000)	-	(113,000)
At 30 June 2021 (unaudited)	93	559,722	27,787	216	123,629	711,447	24,028	735,475

Interim Condensed Consolidated Statement of Cash Flows

For the six months ended 30 June 2022

	Notes	For the six months ended 30 June	
		2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit before tax		131,211	106,011
Adjustments for:			
Finance costs		5,624	4,472
Fair value gains on financial assets at fair value through profit or loss	5	(9,541)	–
Foreign exchange differences, net	5	(991)	(93)
Interest income		(5,206)	(2,650)
Loss on disposal of items of property, plant and equipment, net		6	–
Loss on termination of leases		84	–
Depreciation of property, plant and equipment	5	23,372	21,003
Depreciation of right-of-use assets	5	21,422	17,169
Amortisation of intangible assets	5	2,704	2,548
Impairment of trade receivables	5	1,770	2,370
Impairment of other receivables	5	4,016	2,000
Impairment of amounts due from related parties	5	–	295
Share-based payments		1,489	6,240
(Increase)/decrease in inventories		(11,707)	2,952
Increase in trade receivables		(12,827)	(8,507)
Increase in prepayments, other receivables and other assets		(10,381)	(11,521)
Increase in trade payables		22,680	9,758
Increase in other payables and accruals		10,317	13,469
Decrease/(increase) in amounts due from related parties		19,164	(5,906)
Cash generated from operations		193,206	159,610
Interest received		5,206	2,650
Interest paid		(5,468)	(4,321)
Income tax paid		(36,241)	(30,689)
Net cash flows from operating activities		156,703	127,250

Interim Condensed Consolidated Statement of Cash Flows

For the six months ended 30 June 2022

	Notes	For the six months ended 30 June	
		2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
CASH FLOWS FROM INVESTING ACTIVITIES			
Payments for acquisition of items of property, plant and equipment		(85,032)	(15,777)
Payments for acquisition of intangible assets		(1,039)	(301)
Proceeds from disposal of items of property, plant and equipment		9	1
Purchases of long-term time deposits		(10,531)	–
Purchases of financial assets at fair value through profit or loss		(1,110,000)	–
Proceeds from disposal of financial assets at fair value through profit or loss		1,278,583	–
Decrease in prepayments, other receivables and other assets		–	1,700
Net cash flows from/(used in) investing activities		71,990	(14,377)
CASH FLOWS FROM FINANCING ACTIVITIES			
Repayment of other borrowings		–	(901)
Principal portion of lease payments		(38,154)	(12,816)
Payments of listing expenses		–	(4,311)
Dividends paid		(62,734)	(70,000)
Net cash flows used in financing activities		(100,888)	(88,028)
NET INCREASE IN CASH AND CASH EQUIVALENTS			
Cash and cash equivalents at beginning of period		1,257,136	413,246
Effect of foreign exchange rate changes, net		29,483	93
CASH AND CASH EQUIVALENTS AT END OF PERIOD		1,414,424	438,184
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS			
Cash and bank balances		1,414,424	438,184
Cash and cash equivalents as stated in the interim condensed consolidated statement of cash flows		1,414,424	438,184

Notes to the Interim Condensed Consolidated Financial Information

30 June 2022

1. CORPORATE INFORMATION

The Company is a limited liability company incorporated in the Cayman Islands on 19 May 2020. The registered office address of the Company is 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands.

The Company is an investment holding company. The Company's subsidiaries are involved in the provision of in-patient services, out-patient services, and sales of optical products in the mainland of the People's Republic of China (the "PRC").

2. BASIS OF PREPARATION AND CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

2.1 Basis of presentation

The interim condensed consolidated financial information of the Group for the six months ended 30 June 2022 has been prepared in accordance with International Accounting Standard ("IAS") 34 Interim Financial Reporting issued by the International Accounting Standards Board.

The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2021.

The interim condensed consolidated financial information has been prepared under the historical cost convention, except for financial assets at FVTPL which have been measured at fair value. The financial information is presented in Renminbi ("RMB"), except when otherwise indicated.

2.2 Changes in Accounting Policies and Disclosures

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2021, except for the adoption of the following revised International Financial Reporting Standards ("IFRSs") for the first time for the current period's financial information.

Amendments to IFRS 3

Amendments to IAS 16

Amendments to IAS 37

Annual Improvements to IFRSs 2018-2020

Reference to the Conceptual Framework

Property, Plant and Equipment: Proceeds before Intended Use

Onerous Contracts – Cost of Fulfilling a Contract

Amendments to IFRS 1, IFRS 9, Illustrative Examples accompanying IFRS 16, and IAS 41

Notes to the Interim Condensed Consolidated Financial Information

30 June 2022

2. BASIS OF PREPARATION AND CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (CONTINUED)

2.2 Changes in Accounting Policies and Disclosures (Continued)

The nature and impact of the revised IFRSs are described below:

- (a) Amendments to IFRS 3 replace a reference to the previous *Framework for the Preparation and Presentation of Financial Statements* with a reference to the *Conceptual Framework for Financial Reporting* issued in March 2018 without significantly changing its requirements. The amendments also add to IFRS 3 an exception to its recognition principle for an entity to refer to the Conceptual Framework to determine what constitutes an asset or a liability. The exception specifies that, for liabilities and contingent liabilities that would be within the scope of IAS 37 or IFRIC-Int 21 if they were incurred separately rather than assumed in a business combination, an entity applying IFRS 3 should refer to IAS 37 or IFRIC-Int 21 respectively instead of the Conceptual Framework. Furthermore, the amendments clarify that contingent assets do not qualify for recognition at the acquisition date. The Group has applied the amendments prospectively to business combinations that occurred on or after 1 January 2022. As there were no contingent assets, liabilities and contingent liabilities within the scope of the amendments arising in the business combination that occurred during the period, the amendments did not have any impact on the financial position and performance of the Group.
- (b) Amendments to IAS 16 prohibit an entity from deducting from the cost of an item of property, plant and equipment any proceeds from selling items produced while bringing that asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Instead, an entity recognises the proceeds from selling any such items, and the cost of those items, in profit or loss. The Group has applied the amendments retrospectively to items of property, plant and equipment made available for use on or after 1 January 2021. Since there was no sale of items produced while making property, plant and equipment available for use on or after 1 January 2021, the amendments did not have any impact on the financial position or performance of the Group.
- (c) Amendments to IAS 37 clarify that for the purpose of assessing whether a contract is onerous under IAS 37, the cost of fulfilling the contract comprises the costs that relate directly to the contract. Costs that relate directly to a contract include both the incremental costs of fulfilling that contract (e.g., direct labour and materials) and an allocation of other costs that relate directly to fulfilling that contract (e.g., an allocation of the depreciation charge for an item of property, plant and equipment used in fulfilling the contract as well as contract management and supervision costs). General and administrative costs do not relate directly to a contract and are excluded unless they are explicitly chargeable to the counterparty under the contract. The Group has applied the amendments prospectively to contracts for which it has not yet fulfilled all its obligations at 1 January 2022 and no onerous contracts were identified. Therefore, the amendments did not have any impact on the financial position or performance of the Group.

2. BASIS OF PREPARATION AND CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (CONTINUED)

2.2 Changes in Accounting Policies and Disclosures (Continued)

- (d) Annual Improvements to IFRSs 2018-2020 sets out amendments to IFRS 1, IFRS 9, Illustrative Examples accompanying IFRS 16, and IAS 41. Details of the amendments that are applicable to the Group are as follows:
- IFRS 9 *Financial Instruments*: clarifies the fees that an entity includes when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial liability. These fees include only those paid or received between the borrower and the lender, including fees paid or received by either the borrower or lender on the other's behalf. The Group has applied the amendment prospectively to financial liabilities that are modified or exchanged on or after 1 January 2022. As there was no modification of the Group's financial liabilities during the period, the amendment did not have any impact on the financial position or performance of the Group.
 - IFRS 16 *Leases*: removes the illustration of payments from the lessor relating to leasehold improvements in Illustrative Example 13 accompanying IFRS 16. This removes potential confusion regarding the treatment of lease incentives when applying IFRS 16.

3. OPERATING SEGMENT INFORMATION

The Group is principally engaged in the provision of in-patient services, out-patient services and sales of optical products. For management purposes, the aforesaid businesses are integral and the Group has not organised into different operating segments. Management monitors the results of the Group's operation as a whole for the purpose of making decisions about resource allocation and performance assessment, and accordingly no further operating segment analysis thereof is presented.

Geographical information

As the Group's major operations, customers and non-current assets are located in the People's Republic of China (the "PRC"), no further geographical segment information is provided.

Information about major customers

No revenue from single customers individually accounted for 10% or more of the Group's revenue.

Notes to the Interim Condensed Consolidated Financial Information

30 June 2022

4. REVENUE

An analysis of revenue is as follows:

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
Revenue from contracts with customers	532,742	500,171
Analysed into:		
Basic ophthalmic services	241,691	233,002
Consumer ophthalmic services	291,051	266,495
Others	–	674

(a) Disaggregated revenue information for revenue from contracts with customers

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
<i>Types of goods or services</i>		
In-patient services	174,449	167,025
Out-patient services	319,996	293,474
Sales of optical products	38,297	38,998
Others	–	674
Total revenue from contracts with customers	532,742	500,171

4. REVENUE (CONTINUED)

(a) Disaggregated revenue information for revenue from contracts with customers (Continued)

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
<i>Timing of revenue recognition</i>		
Services and goods transferred at a point in time	358,293	333,146
Services transferred over time	174,449	167,025
Total revenue from contracts with customers	532,742	500,171

5. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
Cost of sales	288,406	272,821
Depreciation of property, plant and equipment	23,372	21,003
Depreciation of right-of-use assets	21,422	17,169
Amortisation of intangible assets	2,704	2,548
Total depreciation and amortisation	47,498	40,720
Impairment of trade receivables, net	1,770	2,370
Impairment of other receivables, net	4,016	2,000
Impairment of amounts due from related parties, net	-	295
Fair value gains on financial assets at fair value through profit or loss	(9,541)	-
Foreign exchange differences, net	(991)	(93)

Notes to the Interim Condensed Consolidated Financial Information

30 June 2022

6. INCOME TAX EXPENSES

The PRC enterprise income tax has been provided at the rate of 25% (six months ended 30 June 2021: 25%) on the estimated assessable income arising in the PRC during the period. No provision for Hong Kong profits tax has been made as the Group did not generate any assessable profits arising in Hong Kong during the period (six months ended 30 June 2021: Nil). Taxes on profits assessable elsewhere have been calculated at the rates of tax prevailing in the countries (jurisdictions) in which the Group operates.

	For the six months ended	
	30 June	
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Current – Mainland China Charge for the period	37,509	28,672
Deferred	(8,059)	(1,332)
Total tax charge for the Period	29,450	27,340

7. DIVIDENDS

	30 June	30 June
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Unaudited)
Final dividend declared and paid	62,734	70,000
Interim dividend declared	–	43,000
	62,734	113,000

The directors do not recommend the payment of an interim dividend for the six months ended 30 June 2022 (six months ended 30 June 2021: RMB43,000,000).

8. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amounts is based on the profit for the period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 707,625,000 (30 June 2021: 550,000,000) in issue during the period, as adjusted to reflect the subdivision of shares on a one-for-forty basis and the capitalisation issue of 123,913,040 shares basis on 7 July 2021.

The Group had no potentially dilutive ordinary shares in issue during the period ended 30 June 2022 and 2021.

The calculations of basic and diluted earnings per share are based on:

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
Earnings		
Profit for the period attributable to ordinary equity holders of the parent for the purpose of the basic and diluted earnings per share calculation	103,598	80,940
	Number of shares For the six months ended 30 June	
	2022 '000 (Unaudited)	2021 '000 (Unaudited)
Shares		
Weighted average number of ordinary shares in issue during the period used in the basic and diluted earnings per share calculation	707,625	550,000

9. PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2022, the Group acquired property, plant and equipment at an aggregate cost of RMB60,638,000 (30 June 2021: RMB24,887,000).

Assets, other than those classified as held for sale, with a net book value of RMB15,000 were disposed of by the Group during the six months ended 30 June 2022 (30 June 2021: RMB1,000), resulting in RMB6,000 loss on disposal (30 June 2021: nil).

Notes to the Interim Condensed Consolidated Financial Information

30 June 2022

10. TRADE RECEIVABLES

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 RMB'000 (Audited)
Within 3 months	38,292	36,716
4 to 6 months	3,958	5,692
7 to 12 months	15,678	6,470
Over 12 months	7,296	5,289
	65,224	54,167

11. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 RMB'000 (Audited)
Within 1 year	55,037	33,889
1 to 2 years	2,300	903
2 to 3 years	857	1,405
Over 3 years	1,288	605
	59,482	36,802

12. SHARE CAPITAL

The Company was incorporated in the Cayman Islands on 19 May 2020 with authorised share capital of HK\$380,000 divided into 1,520,000,000 shares with a par value of HK\$0.00025 each.

	30 June 2022 HK\$'000 (Unaudited)	31 December 2021 HK\$'000 (Audited)
Authorised 1,520,000,000 shares of par value of HK\$0.00025 each	380	380
	RMB'000 (Unaudited)	RMB'000 (Audited)
Issued and fully paid 707,625,000 shares of par value of HK\$0.00025 each	152	152

13. CONTINGENT LIABILITIES

As at 30 June 2022, the Group did not have any contingent liabilities or guarantees that would have a material impact on the financial position or operations of the Group.

14. COMMITMENTS

The Group had the following capital commitments at the end of the reporting period:

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 RMB'000 (Audited)
Contracted, but not provided for: Property, plant and equipment	10,807	21,831

Notes to the Interim Condensed Consolidated Financial Information

30 June 2022

15. RELATED PARTY TRANSACTIONS AND BALANCES

(a) Related party transactions

In addition to the transactions detailed elsewhere in the financial statements, the Group had the following material transactions with related parties during the period and prior period:

	Notes	For the six months ended	
		2022	2021
		RMB'000	RMB'000
		(Unaudited)	(Unaudited)
Lease payments:	(i)		
Entities controlled by controlling shareholders		21,240	5,190
Controlling shareholders		923	923
		22,163	6,113

Notes:

- (i) The pricing for the rental paid to related parties were determined according to the published price. The transactions were conducted in accordance with the terms mutually agreed between the parties.

(b) Outstanding balances with related parties

Due from related parties, net & impairment

	30 June	31 December
	2022	2021
	RMB'000	RMB'000
	(Unaudited)	(Audited)
Trade in nature:		
Entities controlled by controlling shareholders	–	19,164

The amounts due from related parties as at 31 December 2021 are unsecured, interest-free and collectable on demand.

15. RELATED PARTY TRANSACTIONS AND BALANCES (CONTINUED)

(c) Compensation of key management personnel of the Group

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 RMB'000 (Unaudited)
Salaries, allowances and benefits in kind	1,955	1,499
Performance related bonuses	690	765
Pension scheme contributions	127	91
Share-based payments	1,016	2,660
	3,788	5,015

16. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

The carrying amounts and fair values of the Group's financial instruments, other than those with carrying amounts that reasonably approximate to fair values, are as follows:

	Carrying amounts		Fair values	
	30 June 2022 RMB'000 (Unaudited)	31 December 2021 RMB'000 (Audited)	30 June 2022 RMB'000 (Unaudited)	31 December 2021 RMB'000 (Audited)
Financial assets				
Financial assets at fair value through profit or loss	361,001	520,043	361,001	520,043
Financial liabilities				
Other borrowings Non-current portion	736	717	759	737

Notes to the Interim Condensed Consolidated Financial Information

30 June 2022

16. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (CONTINUED)

Management has assessed that the fair values of trade receivables, financial assets included in prepayments, other receivables and other assets, amounts due from related parties, cash and cash equivalents, trade payables, financial liabilities included in other payables and accruals, and lease liabilities approximate to their carrying amounts largely due to the short-term maturities of these instruments or their floating interest rates.

The fair value of long-term deposits has been calculated by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities.

The Group's finance department headed by the finance manager is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The finance manager reports directly to the chief financial officer. At each reporting date, the finance department analyses the movements in the values of financial instruments and determines the major inputs applied in the valuation. The valuation is reviewed and approved by the chief financial officer.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values:

The fair values of the non-current portion of financial liabilities included in other borrowings have been calculated by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities.

16. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (CONTINUED)

Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

Assets measured at fair value:

As at 30 June 2022

	Fair value measurement using			Total RMB'000
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
Financial assets at fair value through profit or loss	–	361,001	–	361,001

As at 31 December 2021

	Fair value measurement using			Total RMB'000
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
Financial assets at fair value through profit or loss	–	520,043	–	520,043

The Group did not have any financial liabilities measured at fair value as at 30 June 2022 (31 December 2021: Nil).

During the period, there were no transfers of fair value measurements between Level 1 and Level 2 and no transfers into or out of Level 3 for both financial assets and financial liabilities (31 December 2021: Nil).

Notes to the Interim Condensed Consolidated Financial Information

30 June 2022

16. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (CONTINUED)

Fair value hierarchy (continued)

Liabilities for which fair values are disclosed:

As at 30 June 2022

	Fair value measurement using			Total RMB'000
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
Other borrowings Non-current portion	–	759	–	759

As at 31 December 2021

	Fair value measurement using			Total RMB'000
	Quoted prices in active markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
Other borrowings Non-current portion	–	737	–	737

17. EVENTS AFTER THE REPORTING PERIOD

From 1 July 2022 and up to the date of this report, the Group subscribed for structured deposit products in the principal amount of RMB490 million in total offered by Bank of China Limited.

18. APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

The interim condensed consolidated financial information was approved and authorised for issue by the board of directors on 29 August 2022.

Definitions & Glossary

In this report, the following expressions have the meanings set out below unless the context otherwise requires:

“Acting-in-concert Agreement”	the acting-in-concert agreement dated June 3, 2019 together with its supplemental agreement dated April 27, 2021 entered into by Mr. Zhang Bozhou, Ms. Zhang Xiaoli, Mr. Zhang Junfeng, Mr. Zhang Fengsheng and Ms. Zhang Yumei
“Audit Committee”	the audit committee of the Board
“Baotou Hospital”	Baotou City Chaoju Eye Hospital Co., Ltd.* (包頭市朝聚眼科醫院有限公司), a limited liability company incorporated in the PRC on May 12, 2016, a subsidiary of the Company
“Board” or “Board of Directors”	the board of Directors of the Company
“BOC”	Bank of China Limited
“CAGR”	compound annual growth rate
“cataract”	a condition involving the clouding or opacification of the natural lens. Cataract is most commonly caused by aging, but may also be caused by other reasons such as malnutrition, diabetes, trauma or radiation. The more opaque the lens the more the quality of vision is reduced. As a common treatment, clear artificial lenses may be implanted as a substitute for the natural lens to restore clear vision
“Chifeng Hospital”	Chaoju (Chifeng) Eye Hospital Co., Ltd.* (朝聚(赤峰)眼科醫院有限公司), a limited liability company incorporated in the PRC on December 19, 2016, or where the context refers to any time prior to the effective date of the incorporation of this entity, its predecessor(s), a subsidiary of the Company
“China” or “PRC”	the People’s Republic of China, but for the purpose of this report and for geographical reference only, references herein to “China” and the “PRC” do not apply to Hong Kong, Macau and Taiwan
“Company” or “the Company”	Chaoju Eye Care Holdings Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands on May 19, 2020
“Corporate Governance Code”	the Corporate Governance Code as set out in Appendix 14 to the Listing Rules
“COVID-19”	Novel coronavirus pneumonia
“Directors”	director(s) of the Company
“East China”	an eastern region of China consisting of Hangzhou, Zhoushan and Zhejiang Province

Definitions & Glossary

“Frost & Sullivan”	Frost & Sullivan (Beijing) Inc., Shanghai Branch Co., a global market research and consulting company, an Independent Third Party
“glaucoma”	an eye condition usually caused by overly high intraocular pressure, which usually causes optic nerve atrophies and visual field defect
“Global Offering”	the Hong Kong Public Offering and the International Offering (both as defined in the Prospectus)
“Group” or the “Group”	the Company together with its subsidiaries
“HK\$”	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
“Hohhot No. 2 Hospital”	Hohhot Chaoju Eye Hospital Co., Ltd.* (呼和浩特朝聚眼科醫院有限公司), a limited liability company incorporated in the PRC on November 3, 2016, or where the context refers to any time prior to the effective date of the incorporation of this entity, its predecessor(s), a subsidiary of the Company
“Hong Kong” or “HK”	the Hong Kong Special Administrative Region of the PRC
“ICBC”	Industrial and Commercial Bank of China Limited
“IFRS”	International Financial Reporting Standards
“Independent Third Party(ies)”	an individual(s) or a company(ies) who or which is/are not connected (within the meaning of the Listing Rules) with any directors, chief executive or substantial shareholders (within the meaning of the Listing Rules) of the Company, its subsidiaries or any of their respective associates
“Inner Mongolia”	the Inner Mongolia Autonomous Region of the PRC, unless the context indicates otherwise
“in-patient service”	treatments of patients who are checked in at hospitals and are hospitalized overnight or for an extended period of time
“IPO Proceeds”	the proceeds obtained by the Company from the Global Offering
“Listing”	the listing of the Shares on the Main Board on July 7, 2021
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
“macula”	the center of the retina where the retina is most sensitive to lights, and is therefore the core area for the sense of vision

“Main Board”	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operates in parallel with GEM of the Stock Exchange
“Model Code”	the Model Code for Securities Transaction by Directors of Listed Issuers as set out in Appendix 10 to the Listing Rules
“myopia”	a type of refractive error also known as nearsightedness, where the patient is unable to see distant objects clearly. Myopia is usually caused by a longer-than-normal eyeball or excessive refractive ability of the crystalline lens, which results in parallel lights focusing at a position before reaching the retina, thus forming a blurred spot when it reaches the retina
“North China”	a northern region of China consisting of Beijing, Tianjin, Hebei Province, Shanxi Province and Inner Mongolia
“November Structured Deposit Products”	the structured deposit products subscribed by the Group on November 17, 2021, the details of which are set out in the announcement of the Company dated November 17, 2021
“ocular fundus”	the interior surface of the eye opposite the crystalline lens, including the retina, optic disc, macula and posterior pole
“ocular surface”	the interface between the functioning eye and the environment, including the outer layer of the cornea, the conjunctiva, and the margin of the eye lids
“ophthalmologist”	a medical doctor who specializes in eye and vision care
“out-patient service”	treatments of patients who are not checked-in at hospitals and stay at the hospital only for a short period of time (usually completed within the day)
“presbyopia”	an eye condition where the patient has difficulty seeing near items clearly due to declines in refractive abilities of the lens. Presbyopia is a result of the aging of the eye, as the lens loses its natural elasticity and therefore its ability to focus on near objects
“Prospectus”	the prospectus of the Company published on June 24, 2021
“Reporting Period”	from January 1, 2022 to June 30, 2022
“RMB” or “Renminbi”	the lawful currency of the PRC

Definitions & Glossary

“Riverhead Capital I”	Riverhead Capital I, L.P. (北京陽光融匯醫療健康產業成長投資管理中心(有限合夥)), a limited liability partnership established under the laws of the PRC on February 9, 2015, a shareholder of the Company, which is controlled by Ms. Zhang Wenwen, one of the non-executive Directors
“Riverhead Runfeng”	Ronghui Yangguang Runfeng, L.P. (北京融匯陽光潤豐投資管理中心(有限合夥)), a limited liability partnership established under the laws of the PRC on March 10, 2016, a shareholder of the Company, which is controlled by Ms. Zhang Wenwen, one of the non-executive Directors
“Scheme”	the share award scheme of the Company as adopted by the Board on May 10, 2022 and as amended from time to time
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended or supplemented from time to time
“Share(s)”	ordinary share(s) in the share capital of the Company with nominal value of HK\$0.00025 each
“Shareholder(s)”	holder(s) of the Shares
“squint”	deviation of the eyes where there is an eye misalignment
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Xiamen Juludazhou Equity Investment”	Xiamen Juludazhou Equity Investment Partnership (Limited Partnership)* (廈門聚鷺達洲股權投資合夥企業(有限合夥)), a limited liability partnership established under the laws of the PRC on April 10, 2020, a shareholder of the Company, which is controlled by Mr. Zhang Bozhou as its sole general partner
“Xiamen Xinkangnuo”	Xiamen Xinkangnuo Management Consulting Co., Ltd.* (廈門信康諾管理諮詢有限公司), a limited liability company established under the laws of the PRC on August 6, 2020, a subsidiary of the Company by way of consolidation of financial statements, which is owned by Mr. Zhang Bozhou as to 26.64%, Ms. Zhang Xiaoli as to 29.03%, Mr. Zhang Junfeng as to 20.67%, Mr. Zhang Fengsheng as to 20.67% and Ms. Zhang Yumei as to 2.99%, respectively
“Xiangshan Hospital”	Xiangshan Chaoju Eye Hospital Co., Ltd.* (象山朝聚眼科醫院有限公司) (formerly known as Xiangshan Renming Eye Diseases Hospital Co., Ltd.* (象山仁明眼病醫院有限公司)), a limited liability company incorporated in the PRC on April 7, 2015, a subsidiary of the Company

* The English translation of the Chinese names denoted in this report is for illustration purposes only. Should there be any inconsistencies, the Chinese name shall prevail.